Consistent dividend payments are a sign of a company’s financial strength. Investors looking for stable, long-term returns often seek businesses that not only pay dividends but also have a strong track record of increasing them. Amgen and Coca-Cola fit the bill, making them standout choices for income-focused investors.
Amgen’s Dividend Growth Reflects Its Strong Business Model
Biotech giant Amgen has been rewarding shareholders with dividends since 2011, steadily increasing payouts ever since. That kind of reliability is what investors crave.
The company’s portfolio is packed with blockbuster drugs, covering a variety of therapeutic areas. In 2024 alone, Amgen had 13 products each generating more than $1 billion in sales. While some face growing competition, others are stepping up. Tezspire, an asthma medication co-marketed with AstraZeneca, brought in $972 million in revenue last year, marking a 71% year-over-year increase. A recent successful phase 3 trial for chronic rhinosinusitis suggests even more revenue potential.
One concern for Amgen has been its weight-loss drug, MariTide. While its phase 2 trial results didn’t quite meet market expectations, the company remains committed. Two phase 3 studies are underway for obesity and diabetes, keeping the door open for future growth in this highly lucrative sector.
Amgen’s research pipeline remains impressive, with 33 late-stage programs in development. Given this depth, the company has a strong foundation to keep producing high-revenue drugs, which should help maintain and even grow its dividend payouts.
Coca-Cola’s Dividend Streak Is Almost Unmatched
Coca-Cola is a household name, and its dividend history speaks for itself. The company has raised its payouts for 63 consecutive years, securing its place among the exclusive Dividend Kings.
Unlike many companies that struggle during economic downturns, Coca-Cola has a proven ability to bounce back. The pandemic temporarily hurt sales, but the company adapted quickly, proving its resilience.
• Coca-Cola’s product lineup extends beyond sodas to bottled water, tea, coffee, sports drinks, and even alcoholic beverages. • The brand operates in over 200 countries, ensuring steady global demand. • A powerful brand reputation helps maintain consumer loyalty and trust.
Coca-Cola also adapts well to changing consumer preferences. As health-conscious choices become more popular, the company continues expanding its low-calorie and non-soda options, ensuring it stays relevant in an evolving market.
Comparing Key Dividend Metrics
For income investors, numbers matter. Here’s how Amgen and Coca-Cola compare on key dividend-related metrics:
| Company | Dividend Yield | Years of Consecutive Increases | Gross Margin |
|---|---|---|---|
| Amgen | 2.97% | 13 years | 66.05% |
| Coca-Cola | 2.79% | 63 years | 61.16% |
Both companies offer attractive dividend yields, but Coca-Cola stands out for its incredible consistency, while Amgen’s higher margins give it a strong cash flow to sustain payouts.
Why These Stocks Are Solid Choices for Dividend Investors
Amgen and Coca-Cola offer different kinds of security for dividend investors. Amgen’s strength lies in its pharmaceutical innovations, ensuring future revenue streams through new drugs. Coca-Cola’s dominance in the beverage industry provides a reliable, steady income source.
With economic uncertainty always looming, these stocks provide a level of stability. Neither is likely to cut dividends anytime soon, making them smart picks for those looking to secure their financial future through dividend investing.
